Arkadios Wealth Advisors Invests $301,000 in United Therapeutics Corporation (NASDAQ:UTHR)

Arkadios Wealth Advisors purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 977 shares of the biotechnology company's stock, valued at approximately $301,000.

Several other institutional investors and hedge funds have also made changes to their positions in UTHR. FMR LLC boosted its stake in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares in the last quarter. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of United Therapeutics during the 1st quarter worth approximately $101,354,000. GAMMA Investing LLC grew its holdings in United Therapeutics by 29,415.2% in the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock valued at $68,422,000 after purchasing an additional 221,202 shares during the period. Northern Trust Corp lifted its stake in United Therapeutics by 29.1% in the 4th quarter. Northern Trust Corp now owns 488,854 shares of the biotechnology company's stock valued at $172,487,000 after buying an additional 110,298 shares in the last quarter. Finally, AustralianSuper Pty Ltd raised its position in shares of United Therapeutics by 49.0% in the first quarter. AustralianSuper Pty Ltd now owns 282,739 shares of the biotechnology company's stock valued at $87,160,000 after buying an additional 92,959 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Down 1.0%

UTHR stock traded down $2.99 during midday trading on Thursday, hitting $299.42. The company's stock had a trading volume of 520,163 shares, compared to its average volume of 601,453. The firm has a 50-day simple moving average of $296.94 and a 200-day simple moving average of $311.89. The firm has a market capitalization of $13.51 billion, a P/E ratio of 11.69, a PEG ratio of 4.58 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter last year, the business posted $5.85 earnings per share. The company's revenue for the quarter was up 11.7% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent research reports. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. UBS Group reduced their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Wells Fargo & Company lowered their price objective on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a research report on Thursday, July 31st. Bank of America dropped their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. Finally, Cantor Fitzgerald assumed coverage on United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target on the stock. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $379.69.

Insider Buying and Selling

In other news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the transaction, the director directly owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 645 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the completion of the sale, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 70,681 shares of company stock worth $21,318,359 over the last 90 days. 10.30% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.